ATV

Atavistik Bio is a clinical-stage biotechnology company focused on discovering and developing precision allosteric therapeutics for oncology and rare diseases. The company utilizes its proprietary AMPS (Allosteric Metabolite-Protein Surface) platform, which integrates high-throughput screening with AI-enabled drug discovery to identify novel allosteric sites on historically "undruggable" targets. Its lead candidate, ATV-1601, is a first-in-class selective allosteric inhibitor of AKT1 currently in Phase 1 clinical trials for AKT1 E17K-mutant solid tumors and being developed for hereditary hemorrhagic telangiectasia (HHT). Atavistik is also advancing a pipeline of other allosteric inhibitors, including a mutant-selective JAK2 inhibitor for myeloproliferative neoplasms, aiming to provide superior efficacy and tolerability compared to traditional orthosteric inhibitors.